Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
The Use of Fourth-generation Optical Coherence Tomography in Multiple Sclerosis: A Review.
The role of kinin B1 and B2 receptors in the persistent pain induced by experimental autoimmune encephalomyelitis (EAE) in mice: Evidence for the involvement of astrocytes.
Sustained TNF production by central nervous system infiltrating macrophages promotes progressive autoimmune encephalomyelitis.
Will Biomarkers Determine What Is Next in Multiple Sclerosis?: Biomarkers in Multiple Sclerosis.
Adolescent-onset Krabbe disease with an initial diagnosis of multiple sclerosis and a novel mutation.
Multiple sclerosis: Insights into pathophysiology and novel therapeutic avenues.
Falls in people with MS-an individual data meta-analysis from studies from Australia, Sweden, United Kingdom and the United States.
Signaling networks in MS: A systems-based approach to developing new pharmacological therapies.
Benefits, safety, and prescription of exercise in persons with multiple sclerosis.
Follow-up nerve conduction studies in CIDP after treatment with IGIV-C: Comparison of patients with and without subsequent relapse.
[Treatment of multiple sclerosis symptoms and exacerbations].
A Sphingosine-1-Phosphate Receptor 1-Directed Agonist Reduces Central Nervous System Inflammation in a Plasmacytoid Dendritic Cell-Dependent Manner.
[Acute disseminated encephalomyelitis (ADEM): its diagnostic criteria and therapy].
Quality of life and employment in persons with multiple sclerosis.
Fingolimod-associated macular edema: resolution by sub-tenon injection of triamcinolone with continued fingolimod use.
Season of infectious mononucleosis and risk of multiple sclerosis at different latitudes; the EnvIMS Study.
Glutamate, Glutamate Receptors, and Downstream Signaling Pathways.
Quantifying Missing Heritability at Known GWAS Loci.
Tolerogenic dendritic cells produced by Lentiviral-mediated CD40- and IL-23p19-specific shRNA can ameliorate experimental autoimmune encephalomyelitis by suppressing Th17 cells.
Development of a short form and scoring algorithm from the validated actionable bladder symptom screening tool.
Interictal interleukin-17A levels are elevated and correlate with seizure severity of epilepsy patients.
New insights into an autoimmune mechanism, pharmacological treatment and relationship between multiple sclerosis and inflammatory bowel disease.
Cost-effectiveness of injectable disease-modifying therapies for the treatment of relapsing forms of multiple sclerosis in Spain.
Nurr1 reduction influences the onset of chronic EAE in mice.
Response to letter regarding article 'Fingolimod effects on left ventricular function in multiple sclerosis'.
Pages
« first
‹ previous
…
396
397
398
399
400
401
402
403
404
…
next ›
last »